COLUMBIA, Md., Nov 24, 2008 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN), a biotechnology drug development
company that is leveraging its Heat Sensitive Liposomal Technology
platform to encapsulate and deliver high concentrations of proven
chemotherapeutics, today announced the appointment of Sean Moran as Sr.
...
COLUMBIA, Md., Nov 17, 2008 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN), a biotechnology drug development
company that is leveraging its Heat Sensitive Liposomal Technology
platform to encapsulate and deliver high concentrations of proven
chemotherapeutics, today announced that President and CEO Michael H.
...
COLUMBIA, Md., Nov 13, 2008 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) today announced financial results for its third quarter ended September 30, 2008. The Company reported a net loss from continuing operations of $4.3 million, or $0.43 per diluted share, compared to a net loss from continuing operations of $3.7 million, or $0.34 per di...
COLUMBIA, Md., Nov 06, 2008 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN), a biotechnology drug development company that is leveraging its Heat Sensitive Liposomal Technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that it would hold a conference call to discuss third quarter resu...
ANDOVER, Mass. and COLUMBIA, Md., Oct 16, 2008 (BUSINESS WIRE) -- Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced the signing of a joint research agreement focusing on a new cancer treatment that combines Philips' ultrasound technology with Celsion's drug delivery solution to target tumors with...
COLUMBIA, Md., Sep 24, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLSN) announced today that its global Phase III Primary Liver Cancer trial is proceeding as planned. In addition to the receipt of FDA agreement in January of 2008 for our pivotal Phase III Primary Liver Cancer trial in the United States, the Company reports that it has obt...
COLUMBIA, Md., Aug 18, 2008 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN: Michael H. Tardugno, President and Chief Executive Officer) and Yakult Honsha Co., Ltd. (Yakult: Mr. Sumiya Hori, President) today announce that Yakult will commence pre-clinical and clinical studies of ThermoDox(R) to support requirements for drug registration in Jap...
COLUMBIA, Md., Aug 18, 2008 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) today announced financial results for its second quarter ended June 30, 2008. The Company reported a net loss from continuing operations of $2.4 million, or $0.24 per diluted share, compared to a net loss from continuing operations of $4.6 million, or $0.43 per dilute...
COLUMBIA, Md., Aug 11, 2008 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN), a biotechnology, drug development company that is leveraging its Heat Sensitive Liposomal Technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today reported that it would hold a conference call to discuss second quarter res...
COLUMBIA, Md., Jul 29, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLSN) announced that its docetaxel thermosensitive liposome preclinical study results were presented at the 11th Liposome Research Days Conference during the poster session on July 22, 2008.
The well attended presentation provided detailed preclinical results regarding ...
COLUMBIA, Md., Jun 30, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLSN) will join the Russell Microcap Index when Russell Investments reconstitutes its family of U.S. indexes on June 30, according to a list of additions posted on www.russell.com.
Membership in the Russell Microcap Index, which remains in place for one year, means auto...
COLUMBIA, Md., Jun 27, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) announced today that the interim results from its second Phase I liver cancer confirmation study of ThermoDox in combination with Radio Frequency Ablation (RFA) treating patients with primary and metastatic liver cancer were presented at both Oral and Poster presentati...
COLUMBIA, Md., Jun 23, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) announced today the change of its NASDAQ stock ticker symbol from CLN to CLSN. The new ticker symbol will go into effect at the start of trading on June 30, 2008.
"We are pleased to announce our new ticker symbol, one that we believe will improve our visibility wit...
COLUMBIA, Md., Jun 12, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) announced today that its docetaxel thermosensitive liposome preclinical study results will be presented at the 11th Liposome Research Days Conference. This LRD (Liposome Research Days) conference will be held from July 19 - 22, 2008 in Yokohama, Japan.
The presenta...
COLUMBIA, Md., May 15, 2008 (BUSINESS WIRE) -- Insert time of meeting in first graph so that it reads: CELSION CORPORATION (NASDAQ: CLN), will hold its Annual Meeting of Stockholders on Wednesday, May 21, 2008 at 10AM Eastern Time at the InterContinental Harbor Court Baltimore, 550 Light Street, Baltimore, MD 21202.
The corrected release reads:...
COLUMBIA, Md., May 08, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) today announced financial results for the first quarter ended March 31, 2008. The Company reported a net loss of $4.1 million, or $0.40 per share, compared to a net loss of $2.4 million, or $0.30 per share, for the first quarter of 2007. The results for 2007 included i...
COLUMBIA, Md., May 05, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN), a biotechnology, drug development company that is leveraging its Heat Sensitive Liposomal Technology platform to encapsulate and deliver a high concentrations of proven chemotherapeutics, today reported that It would hold a shareholders' conference call at 11:00 a.m. ...
COLUMBIA, Md., Apr 21, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) announced today that the interim results from its second Phase I liver cancer confirmation study of ThermoDox in combination with Radio Frequency Ablation (RFA) treating patients with primary and metastatic liver cancer will be presented at both Oral and Poster present...
